A Study of Endostar in Combination With Chemotherapy Followed by Endostar Maintenance Therapy in Patients With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC)
All eligible patients will receive Endostar in combination with Gemcitabine plus
Platinum-based chemotherapy for 4 cycles (21 days for each cycle). Endostar treatment will
continue after completion of chemotherapy cycles until disease progression. Efficacy will be
evaluated every two cycles.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression Free Survival (PFS)
Yiping Zhang, Dr.
Zhejiang Cancer Hospital
China: Ethics Committee